槲芪癥消汤对H22肝癌小鼠皮下瘤的影响  

Effect of Huqizhengxiao decoction on subcutaneous tumor in H22 hepatoma mice

作　　者：刘迪 姚杨 张旻玥 柴梦音 寇卜心 刘晓霓 汪晓军 Liu Di;Yao Yang;Zhang Minyue;Chai Mengyin;Kou Buxin;Liu Xiaoni;Wang Xiaojun(Center of Integrated Traditional Chinese and Western Medicine,Beijing You-An Hospital,Capital Medical University,Beijing 100069,China;Beijing Institute of Hepatology,Beijing 100069,China)

机构地区：[1]首都医科大学附属北京佑安医院中西医结合中心,北京100069 [2]北京肝病研究所,北京100069

出　　处：《中华肝胆外科杂志》2025年第2期126-132,共7页Chinese Journal of Hepatobiliary Surgery

基　　金：首都卫生发展科研专项(首发2022-2-2186);国家中医药管理局高水平中医药重点学科建设(zyyzdxk-2023002)。

摘　　要：目的探讨槲芪癥消汤对小鼠H22皮下瘤的影响及其可能的作用机制。方法取BALB/c近交系小鼠25只,4~6周龄,健康雄性,体重(20±2)g,其中1只用于H22肝癌细胞扩增,将扩增的H22肝癌细胞接种于剩余小鼠左侧腋后线皮下建模,将24只建模成功的小鼠分为4组:对照组、索拉非尼组、槲芪癥消汤组和联合用药(索拉非尼+槲芪癥消汤)组,每组6只。比较各组小鼠的抑瘤率、血清天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)。免疫组化和蛋白质印迹法检测各组小鼠瘤组织中白细胞介素(IL)-6、信号转导及转录激活蛋白3(STAT3)、磷酸化的STAT3(p-STAT3)、核苷酸结合寡聚化结构域样受体蛋白3(NLRP3)的表达。酶联免疫吸附实验检测瘤组织IL-6、肿瘤坏死因子-α(TNF-α)、IL-1β的表达。实时荧光定量聚合酶链反应检测瘤组织IL-6、STAT3、趋化因子(C-X-C基序)配体1(CXCL1)mRNA的表达。结果联合用药组的瘤质量(0.50±0.22)g和瘤体积(0.37±0.18)cm 3较对照组的瘤质量(1.63±0.26)g和瘤体积(0.98±0.83)cm 3降低最为明显,差异具有统计学意义(均P<0.05)。索拉非尼组、槲芪癥消汤组和联合用药组的抑瘤率分别为35.4%、48.6%和69.7%。与对照组相比,各治疗组小鼠血清AST、ALT水平均下降,其中联合用药组下降最多[AST:(48.81±2.82)U/L比(188.12±6.51)U/L;ALT:(34.14±1.25)U/L比(116.62±4.72)U/L],差异均具有统计学意义(均P<0.05)。各治疗组小鼠瘤组织的IL-6、STAT3、p-STAT3、IL-1β、TNF-α、NLRP3蛋白表达较对照组均有减少,以联合用药组减少最为明显,差异均有统计学意义(均P<0.05)。与对照组相比,各治疗组小鼠瘤组织IL-6、STAT3、CXCL1的mRNA表达水平也均有降低,且联合用药组低于单一用药组,差异均具有统计学意义(均P<0.05)。结论槲芪癥消汤可以通过抑制IL-6/STAT3通路的激活,改善肿瘤炎症环境,对肿瘤起抑制作用。Objective To investigate the inhibitory effect of Huqizhengxiao decoction(HQZXD)on subcutaneous tumor in H22 hepatoma-bearing mice and its potential mechanism.Methods Twenty-five healthy male BALB/c inbred mice aged 4 to 6 weeks and weighing(20±2)g were taken.One of them was used for the amplification of H22 hepatoma cells.The amplified H22 hepatoma cells were inoculated subcutaneously at the left posterior axillary line of the remaining mice for modeling.After subcutaneous tumor formation,the mice were randomly divided into four groups:model group,HQZXD group,sorafenib group and combined(HQZXD+sorafenib)group,with 6 mice in each group.Tumor inhibition rates,and serum levels of aspartate transaminase(AST)and alanine transaminase(ALT)were observed.The expression of interleukin(IL)-6,signal transducer and activator of transcription 3(STAT3),phosphorylated STAT3(p-STAT3),and nucleotide-binding oligomerization domain-like receptor protein 3(NLRP3)in tumor tissues was detected using immunohistochemistry and Western blotting.Enzyme-linked immunosorbent assay was used to quantify the levels of IL-6,tumor necrosis factor-alpha(TNF-α),and IL-1βin tumor tissues.Quantitative real-time polymerase chain reaction(qRT-PCR)was employed to assess the mRNA levels of IL-6,STAT3,and C-X-C motif chemokine ligand 1(CXCL1)in tumor tissues.Results The general condition of mice in all treatment groups improved compared to the model group.Notably,the tumor weight(0.50±0.22)g and tumor volume(0.37±0.18)cm 3 in the combined group were significantly lower than those in the model group[tumor weight:(1.63±0.26)g,tumor volume:(0.98±0.83)cm 3]with statistical significance(both P<0.05).The tumor inhibition rates for the sorafenib,HQZXD,and combination groups were 35.4%,48.6%,and 69.7%,respectively.Compared to the model group,serum levels of AST and ALT were reduced in all treatment groups,with the combined group showing the most significant decrease[AST:(48.81±2.82)U/L vs.(188.12±6.51)U/L;ALT:(34.14±1.25)U/L vs.(116.62±4.72)U/L],and th

关 键 词：癌 肝细胞 白介素-6 转录激活蛋白3 索拉非尼 槲芪癥消汤 

分 类 号：R73[医药卫生—肿瘤]